Cimetidine-induced psychosis in a 14-year-old girl.

Por Papp, K A, Curtis, R M
Publicado em 1984

Phase I randomized study of KHK4083, an anti‐OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis

Por Papp, K.A., Gooderham, M.J., Girard, G., Raman, M., Strout, V.
Publicado no J Eur Acad Dermatol Venereol (2017)

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

Por Papp, K.A., Barber, K., Bissonnette, R., Bourcier, M., Lynde, C.W., Poulin, Y., Shelton, J., Garces, K., Toole, J., Poulin‐Costello, M.
Publicado no J Eur Acad Dermatol Venereol (2015)

Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Por Menter, A., Papp, K.A., Gooderham, M., Pariser, D.M., Augustin, M., Kerdel, F.A., Fakharzadeh, S., Goyal, K., Calabro, S., Langholff, W., Chavers, S., Naessens, D., Sermon, J., Krueger, G.G.
Publicado no J Eur Acad Dermatol Venereol (2016)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

Por Blauvelt, A., Papp, K.A., Sofen, H., Augustin, M., Yosipovitch, G., Katoh, N., Mrowietz, U., Ohtsuki, M., Poulin, Y., Shrom, D., Burge, R., See, K., Mallbris, L., Gordon, K.B.
Publicado no J Eur Acad Dermatol Venereol (2017)